Stocks TelegraphStocks Telegraph
Stock Ideas

GNMSF Company Profile and Key Details

PNK : GNMSF

Genmab A/S

$268.61
00
At Close 4:00 PM
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Genmab A/S (GNMSF) stock remained unchanged at $249.28 a share on OTC. The stock opened at $250.00, fluctuating between $249.00 to $250.00 during the session.

Stock Snapshot

249.28
Prev. Close
15.3B
Market Cap
249
Day Low
18.96
P/E Ratio
13.15
EPS (TTM)
107.21
Cash Flow per Share
250
Open
61.39M
Number of Shares
250
Day High
98.83%
Free Float in %
483.85
Book Value
178
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jun 17, 2026249.28249.28249.28249.281
Jun 09, 2026250.00252.50247.82249.00228
Jun 05, 2026249.45249.45249.45249.451
Jun 04, 2026241.82241.82241.82241.8253
Jun 03, 2026232.50232.50232.50232.50254
May 28, 2026251.55251.55251.55251.551
May 26, 2026260.00260.00260.00260.001.68K
May 22, 2026258.12258.12258.12258.123
May 20, 2026269.50269.50269.50269.50160
May 14, 2026265.27265.27265.27265.277
May 13, 2026268.24268.24268.24268.244
May 12, 2026264.64264.64264.64264.6418
May 11, 2026257.51259.60251.75259.6071
May 08, 2026259.32259.32259.32259.328.01K
May 07, 2026273.14273.14270.60270.6088K
May 06, 2026270.00275.00270.00275.00901
May 05, 2026270.00270.00270.00270.00297
May 04, 2026261.00261.00261.00261.00215
Apr 30, 2026265.00265.00255.33255.3316.42K
Apr 28, 2026255.25255.25255.25255.2515

Contact Details

Copenhagen, 1560

Denmark

https://www.genmab.com457 020 2728

About Company

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Company Information

Employees2638
Beta0.74
Sales or Revenue$16.47B
5Y Sales Change%4.109%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Stock Peers

ODTC
00
Odonate Therapeutics, Inc.$2,849.50CMXHF
00
CSL Limited$192.00NONOF
00
Novo Nordisk A/S$144.95CSLLY
0.75+0.79%
CSL Limited$95.35UCBJY
-0.06-0.08%
UCB SA$73.15PHMMF
4.3+16.01%
Pharma Mar, S.A.$31.15BVNKF
00
Bavarian Nordic A/S$21.20NURPF
00
Neuren Pharmaceuticals Limited$14.00ELOX
0.05+0.36%
Eloxx Pharmaceuticals, Inc.$13.98TLPPF
00
Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently mid-range between its 52-week high and low $198.51 and $352.00. With a market capitalization of about $15.30 billion, Genmab A/S is classified as a large-cap and shows lower-than-market volatility (beta ~0.68). Key stats such as the average daily volume over the past year has been around 1.89 thousand shares, volume is running light vs its 52-week average. Headquartered in Copenhagen, None, Genmab A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jan van de Winkel, the company employs approximately 2,638 people and listed since January 05, 2010. Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases.

Technical Performance

Average 10-day trading volume of 114.50 shares is below the 3-month average of 4.19 thousand, indicating normal recent market interest.

Valuation Metrics

Genmab A/S trades at a P/E ratio of 18.65, slightly below the S&P 500 average, with a price-to-sales ratio of 3.93 and a price-to-book ratio of 2.69 suggesting the stock is closer to book value. The P/FCF stands at 17.53, also above market averages.

Dividend & Fair Value

Genmab A/S last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $67.04. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Genmab A/S earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -46.79%. The prior quarter beat by -81.85%. Over the last six quarters, Apple has recorded several small beats. These include 1125.02% in February 12, 2025.

Price Forecast & Outlook

Our AI price prediction model suggests that Genmab A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Genmab A/S trading at a premium to the broader market with a P/E of 18.65.

Frequently Asked Questions

What is the current Genmab A/S (GNMSF) stock price?
Genmab A/S (OTC: GNMSF) stock price is $249.28 in the last trading session. During the trading session, GNMSF stock reached the peak price of $250.00 while $249.00 was the lowest point it dropped to. The percentage change in GNMSF stock occurred in the recent session was 0% while the dollar amount for the price change in GNMSF stock was $0.00.
GNMSF's industry and sector of operation?
The OTC listed GNMSF is part of Biotechnology industry that operates in the broader Healthcare sector. Genmab A/S designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of GNMSF?
Mr. Anthony Mancini
Executive Vice President & Chief Operating Officer
Ms. Birgitte Stephensen M.Sc.
Executive Vice President & Chief Legal Officer
Mr. Anthony Pagano
Executive Vice President & Chief Financial Officer
Dr. Tahamtan Ahmadi
Executive Vice President, Chief Medical Officer & Head of Experimental Medicines
Mr. Andrew Carlsen
Senior Director, Vice President & Head of Investor Relations
Dr. Jan G.J. van de Winkel Ph.D.
Co-Founder, Pres & Chief Executive Officer
Dr. Judith V. Klimovsky M.D.
Executive Vice President & Chief Devel. Officer
Dr. Rima Bawarshi Nassar Ph.D.
Vice President, Head of Global Regulatory Affairs – Oncology & Non-Independent Director
Mr. Martin Schultz
Senior Director of Clinical Operations & Non-Independent Director
Mr. Christopher Cozic
Executive Vice President & Chief People Officer
Dr. Mijke Zachariasse Ph.D.
Senior Director, Head of Antibody Research Materials & Non-Independent Director
Mr. Takahiro Hamatani
Senior Director of Fin. Japan & Non-Independent Director
Mr. Peter Ros
Vice President of Fin.
How GNMSF did perform over past 52-week?
GNMSF's closing price is 2.52% higher than its 52-week low of $198.51 where as its distance from 52-week high of $352.00 is -36.24%.
How many employees does GNMSF have?
Number of GNMSF employees currently stands at 2,638.
Link for GNMSF official website?
Official Website of GNMSF is: https://www.genmab.com
How do I contact GNMSF?
GNMSF could be contacted at phone 457 020 2728 and can also be accessed through its website. GNMSF operates from Kalvebod Brygge 43, Copenhagen, 1560, Denmark.
How many shares of GNMSF are traded daily?
GNMSF stock volume for the day was 178 shares. The average number of GNMSF shares traded daily for last 3 months was 1.89K.
What is the market cap of GNMSF currently?
The market value of GNMSF currently stands at $15.30B with its latest stock price at $249.28 and 61.39M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph